Search clinical trials for: VGB-Ex01

Total 531 results

BeiGene

Completed

First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Not Determined

Australia, China
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
BeiGene

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Australia New Zealand Gynaecological Oncology Group
BeiGene

Withdrawn

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)

Ovarian Cancer | Carcinosarcoma
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
BeiGene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Autoimmune Diseases | Healthy Volunteers | Healthy Subjects | Healthy Participants | Healthy Adult Participants
Sana Klinikum Offenbach

Terminated

One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass (MGBvsRYGB)

Obesity

Germany
Mario Musella MD

Unknown

MGB/OAGB and LSG Effects on Lower Esophageal Sphincter (LES) Function

Gastroesophageal Reflux | Morbid Obesity | Bariatric Surgery Candidate

Italy
BeiGene

Recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)

United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
BeiGene

Active, not recruiting

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Mature B-cell Malignancies

China
BeiGene

Withdrawn

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Glutaric Acidemia Type I | Glutaric Aciduria Type I

China
BeiGene

Completed

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Healthy Volunteers

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
BeiGene

Active, not recruiting

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Solid Tumor

Australia, United States
Klinik Hirslanden, Zurich

Recruiting

Intelligent Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer (VISION I)

Breast Cancer

Switzerland
Rambam Health Care Campus

Recruiting

Sarcopenia in Older Patients in the Acute Hospital Setting

Frailty | Sarcopenia

Israel
CAGE Bio Inc.
ethica Clinical Research Inc.

Completed

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

Rosacea

United States
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, France, Australia
BeiGene

Withdrawn

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Solid Tumors
Nantes University Hospital
Direction Générale de l'Offre de Soins

Completed

CCA of SGB PCR Versus SGB Culture at 35-38 SA in the Optimization of Intrapartum Antibiotic Prophylaxis (DEPIST2P)

Streptococcus Agalactiae

France
BeiGene

Recruiting

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Advanced Solid Tumors

United States, Australia, Spain
BeiGene

Recruiting

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China, United States, Australia, New Zealand, Korea, Republic of
Emory University
US Department of Veterans Affairs

Recruiting

Sympathetic Overactivity in Post-traumatic Stress Disorder (SO-PTSD)

Prehypertension | Post-traumatic Stress Disorder

United States
Zhang Xiaofeng,MD
Zeno Therapeutics Pte. Ltd

Not yet recruiting

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Pancreatic Cancer | Advanced Biliary Cancer
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
Inovio Pharmaceuticals

Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (REVEAL 1)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Portugal, Italy, Philippines, Thailand, Slovakia, Lithuania, Estonia, Belgium, South Africa, Germany, Argentina, United Kingdom, Poland, Puerto Rico, Finland, Mexico, Peru
Amgen

Recruiting

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Sjögren's Syndrome (SS)

United States
SpringWorks Therapeutics, Inc.

Recruiting

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Advanced Solid Tumor

United States, Australia
Inovio Pharmaceuticals

Completed

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Anal Neoplasm

United States, Canada
Göteborg University
Imperial College London

Completed

Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity (LOK)

Morbid Obesity

Sweden
Taipei Veterans General Hospital, Taiwan

Completed

The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

Taiwan
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
BeiGene
SpringWorks Therapeutics, Inc.

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Solid Tumor, Adult

Australia, United States
BeiGene

Completed

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Advanced Cancer

United States, Taiwan, Australia, Korea, Republic of, New Zealand
Inovio Pharmaceuticals

Completed

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Healthy

United States
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
BeiGene

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China, Korea, Republic of, United States
BeiGene

Enrolling by invitation

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Turkey, Korea, Republic of
Hanmi Pharmaceutical Company Limited

Unknown

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Korea, Republic of
Amgen

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

Israel, Chile, United States, Argentina, Canada, Japan, Korea, Republic of
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
Inovio Pharmaceuticals

Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
Gedeon Richter Plc.

Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Bioequivalence

United Kingdom
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males

Healthy

Korea, Republic of
Vascular Graft Solutions Ltd.

Completed

Vein External Support Trial (VEST)

Coronary Heart Disease

United Kingdom
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01)

Hepatitis C, Chronic

Korea, Republic of

Search clinical trials for: VGB-Ex01

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations